Friday, June 5, 2026
Agentic Daily
Pfizer didn't build its AI drug-discovery stack in-house — it licensed Chai Discovery's.
Pharmaceutical Technology reports Pfizer licensing Chai Discovery's AI platform for production drug-discovery operations, normalizing the buy-side answer to every pharma R&D leader's build-or-buy question on AI-molecular tooling. Pull Chai's license terms before the Q3 budget cycle and benchmark them against your internal AI-platform build estimate — the Pfizer reference resets the conversation in every BD meeting from here.
The Phase 2 readout from the ~200-participant follow-on study Cambridge has already initiated. If the immunogenicity signal holds against multiple Sarbeco strains — not just SARS-CoV-2 — the AI-designed-antigen platform graduates from "interesting proof of concept" to "regulatory pathway question," and FDA/MHRA guidance on AI-designed biologics moves from theoretical to urgent. If the immune response is narrow or attenuates fast, the platform story collapses back into a single-program win.
The week AI stopped being something you deploy and became something you can't account for
Anthropic admits Claude now writes most of its own code, bots just beat humans for control of the open web, and finance teams can't reconcile a token bill — the through-line is loss of human-legible accounting, not loss of control.